COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
15 hedge funds and large institutions have $90.5K invested in COSCIENS Biopharma Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
17% more capital invested
Capital invested by funds: $77K → $90.5K (+$13.5K)
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.02% less ownership
Funds ownership: 0.87% → 0.85% (-0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.24K |
| 2 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
+$475 |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$106 |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$90 |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.34K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$1.25K |
| 3 |
GWM
Graybill Wealth Management
Elmhurst,
Illinois
|
-$141 |
| 4 |
Morgan Stanley
New York
|
-$7 |
CSCI Hedge Fund Activity: Q2 2025 in Review
15 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2025, worth a combined $90.5K — up 17% from $77K a quarter earlier.
Fund positioning in CSCI was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $1.24K. The largest seller was Susquehanna International Group, cutting an estimated $1.34K.
- 15 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $90.5K of COSCIENS Biopharma Inc. Common Stock stock for Q2 2025, up 17% quarter-over-quarter.
- 1 fund opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2025 and 1 closed out, a net change of 0 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2025 was Royal Bank of Canada, an estimated $1.24K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2025 was Susquehanna International Group, an estimated $1.34K sold.
Based on aggregated 13F filings for Q2 2025.